Paradoxical metastatic progression following 3months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer-Reference-Cited by-同舟云学术

Paradoxical metastatic progression following 3months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer

Published:2013-05 Issue:2 Volume:107 Page:123-128
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Denham James W.,Steigler Allison,Tai Keen-Hun,Joseph David,Matthews John,Atkinson Chris,Spry Nigel A.,Turner Sandra,North John,Christie David,Wynne Chris,Lamb David S.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference21 articles.

1. Phase III Radiation Therapy Oncology Group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate;Pilepich;Int J Radiat Oncol Biol Phys,2001

2. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial;Denham;Lancet Oncol,2005

3. PSA response signatures – a powerful new prognostic indicator after radiation for prostate cancer?;Denham;Radiother Oncol,2009

4. A proportional hazards model for the subdistribution of a competing risk;Fine;J Am Stat Assoc,1999

5. Cell kinetic measurements in prostate cancer;Haustermans;Int J Radiat Oncol Biol Phys,1997

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A biodegradable rectal balloon implant to protect the rectum during prostate cancer radiotherapy for a patient with active Crohn’s disease;Technical Innovations & Patient Support in Radiation Oncology;2018-06

2. Dynamics of rectal balloon implant shrinkage in prostate VMAT;Strahlentherapie und Onkologie;2017-10-16

3. Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial;Radiotherapy and Oncology;2015-06

4. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial;The Lancet Oncology;2014-09

5. Picking the Optimal Duration of Hormonal Therapy in Men With High-Risk and Locally Advanced Prostate Cancer Treated With Radiotherapy;Seminars in Radiation Oncology;2013-07